Regorafenib — CAS 755037-03-7

Regorafenib is a high-purity Active Pharmaceutical Ingredient (API) classified under Multikinase Inhibitor / Antineoplastic Agent. Mediocon Inc manufactures GMP-compliant Regorafenib at its state-of-the-art facility in Aurangabad, Maharashtra, India, supplying pharmaceutical companies worldwide with consistent quality and full regulatory documentation.

• Metastatic colorectal cancer (mCRC) treatment
• Hepatocellular carcinoma (HCC) therapy
• Gastrointestinal stromal tumours (GIST)
• Multi-targeted kinase inhibition (VEGFR, RAF, PDGFR)

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support